• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ESC/WCC: No Peripheral Arterial Disease Benefit for Coumadin-Aspirin

Article

BARCELONA, Spain -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.

BARCELONA, Spain, Sept. 6 -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.

Four percent of patients randomized to Coumadin (warfarin) plus aspirin had life-threatening bleeding events versus 1.2% of patients treated with aspirin alone (P

The WAVE study recruited 2,161 patients and evenly randomized them to the Coumadin-plus-aspirin regimen or aspirin alone. The average age of patients was 64, and 74% were women. Twenty-nine percent of the participants were current smokers, and 81% had limb peripheral arterial disease. The average blood pressure in both arms was 137/78 mm Hg. At baseline, 98% of the participants were on antiplatelet therapy.

In each group treatment was titrated to reach International Normalization Ratio (INR) levels of 1.8 to 3.5.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.